Creative Medical Technology Holdings (CELZ) Research & Development (2016 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Research & Development of $541658.0 for Q1 2026, down 27.13% year-over-year from $743304.0 in Q1 2025, and down 1.53% quarter-over-quarter from $550077.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Research & Development (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Research & Development for 9 consecutive years, with $541658.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 27.13% year-over-year to $541658.0; the TTM figure through Mar 2026 stood at $2.1 million (down 24.38% YoY), while the FY2025 annual figure was $2.3 million, down 5.87% from the prior year.
- Research & Development eased to $541658.0 in Q1 2026 per CELZ's latest filing, from $550077.0 in the prior quarter.
- Across five years, Research & Development topped out at $5.4 million in Q4 2022 and bottomed at $10000.0 in Q1 2022.
- Historically, Research & Development has averaged $790689.6 across 5 years, with a median of $501261.0 in 2025.
- Annual changes were most pronounced in 2022 — Research & Development surged 10636.44% — and 2023, when it slumped 93.49%.
- Creative Medical Technology Holdings' Research & Development stood at $5.4 million in 2022, then plunged by 93.49% to $349408.0 in 2023, then jumped by 35.04% to $471840.0 in 2024, then gained by 16.58% to $550077.0 in 2025, then decreased by 1.53% to $541658.0 in 2026.
- Business Quant data shows CELZ's Research & Development at $541658.0 in Q1 2026, $550077.0 in Q4 2025, and $465154.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 459,200.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 459,200.00 |
| Mar 31, 2026 | 541,658.00 |
| Dec 31, 2025 | 550,077.00 |
| Sep 30, 2025 | 465,154.00 |
| Jun 30, 2025 | 501,261.00 |
| Mar 31, 2025 | 743,304.00 |
| Dec 31, 2024 | 471,840.00 |
| Sep 30, 2024 | 581,796.00 |
| Jun 30, 2024 | 924,749.00 |
| Mar 31, 2024 | 422,392.00 |
| Dec 31, 2023 | 349,408.00 |
| Sep 30, 2023 | 992,722.00 |
| Jun 30, 2023 | 309,480.00 |
| Mar 31, 2023 | 319,029.00 |
| Dec 31, 2022 | 5.37 Mn |
| Sep 30, 2022 | 230,940.00 |
| Jun 30, 2022 | 659,695.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 59,180.00 |